抗不安薬の世界市場：産業分析、規模、シェア、成長、動向、予測（2024～2032年）

世界の抗不安薬の市場規模は、2023年に157億4,000万米ドルに達し、2024～2032年にかけてCAGR 5.28%で成長し、2032年には約250億1,000万米ドルに達すると予測されています。

抗不安薬は抗不安剤としても知られ、不安障害の症状を緩和するために開発された薬です。これらの障害は、過度の心配、恐怖、神経過敏を特徴とする精神的健康状態であり、しばしば大きな苦痛や日常機能の障害をもたらします。これらの薬剤は中枢神経系に作用して不安症状の強さを軽減します。

市場力学

抗不安薬市場は、相互に関連するいくつかの要因によって推進されています。メンタルヘルス問題に対する世界の認識と受容の高まりは、不安障害の有病率の増加と相まって、抗不安薬の需要拡大に寄与しています。医薬品の研究開発における継続的な進歩は、新規化合物や製剤の発見につながり、これらの医薬品の有効性を高めています。不安障害に対する感受性の高さを特徴とする世界人口の高齢化は、市場の成長をさらに後押ししています。さらに、ストレスレベルの上昇を伴う現代のライフスタイル、拡大するヘルスケアインフラ、メンタルヘルス研究を支援する規制環境の変化が市場の拡大に寄与しています。処方率の増加や、遠隔医療やデジタルヘルスなどの治療方法における技術的進歩も、極めて重要な役割を果たしています。しかし課題としては、過剰処方や副作用の可能性に対する懸念、治療や生活習慣への介入を含む包括的なメンタルヘルスアプローチの必要性などが挙げられます。

調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析を取り上げています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは抗不安薬の世界市場における各セグメントを包括的に評価することもできます。抗不安薬業界の成長と動向は、この調査に全体的なアプローチを提供します。

市場セグメンテーション

抗不安薬市場レポートのこのセクションでは、国および地域レベルのセグメントに関する詳細なデータを提供し、それによって戦略家は、今後の機会で、それぞれの製品やサービスのターゲット層を識別するのに役立ちます。

地域分析

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける抗不安薬市場の現在と将来の需要を強調する地域展望をカバーしています。さらに、本レポートは、すべての主要地域における個々のアプリケーションセグメントの需要、推定・予測に焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

• 市場のハイライト
• 世界市場スナップショット

第3章 抗不安薬 - 業界分析

• イントロダクション：市場力学
• 市場促進要因
• 市場抑制要因
• 市場機会
• 業界動向
• ポーターのファイブフォース分析
• 市場魅力度分析

第4章 バリューチェーン分析

• バリューチェーン分析
• 原材料分析
  • 原材料リスト
  • 原材料メーカーリスト
  • 主要原材料の価格動向
• 潜在的バイヤーのリスト
• マーケティングチャネル
  • ダイレクトマーケティング
  • インダイレクトマーケティング
  • マーケティングチャネル発展動向

第5章 抗不安薬の世界市場分析：薬剤クラス別

• 概要：薬剤クラス別
• 実績データと予測データ
• 分析：薬剤クラス別
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Benzodiazepines
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
• Beta Blockers

第6章 抗不安薬の世界市場分析：流通チャネル別

• 概要：流通チャネル別
• 実績データと予測データ
• 分析：流通チャネル別
• 病院薬局
• 小売薬局／ドラッグストア
• オンライン薬局

第7章 抗不安薬の世界市場分析：地域別

• 展望：地域別
• イントロダクション
• 北米売上分析
  • 概要、実績と予測
  • 北米：セグメント別
  • 北米：国別
  • 米国
  • カナダ
  • メキシコ
• 欧州売上分析
  • 概要、実績と予測
  • 欧州：セグメント別
  • 欧州：国別
  • 英国
  • フランス
  • ドイツ
  • イタリア
  • ロシア
  • その他の欧州
• アジア太平洋売上分析
  • 概要、実績と予測
  • アジア太平洋：セグメント別
  • アジア太平洋：国別
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア
  • 東南アジア
  • その他のアジア太平洋
• ラテンアメリカ売上分析
  • 概要、実績と予測
  • ラテンアメリカ：セグメント別
  • ラテンアメリカ：国別
  • ブラジル
  • アルゼンチン
  • ペルー
  • チリ
  • その他のラテンアメリカ
• 中東・アフリカ売上分析
  • 概要、実績と予測
  • 中東・アフリカ：セグメント別
  • 中東・アフリカ：国別
  • サウジアラビア
  • アラブ首長国連邦
  • イスラエル
  • 南アフリカ
  • その他の中東・アフリカ

第8章 抗不安薬企業の競合情勢

• 抗不安薬市場の競合
• 提携・協力・合意
• 合併・買収
• 新製品の上市
• その他の開発

第9章 企業プロファイル

• 上位企業の市場シェア分析
• 市場集中度
• Pfizer Inc.
• Eli Lilly and Company
• GlaxoSmithKline plc
• Johnson & Johnson
• AstraZeneca plc
• Roche Holding AG
• Forest Laboratories（a subsidiary of Allergan
• now part of AbbVie）
• Bristol Myers Squibb Company
• Sanofi S.A.
• Lundbeck A/S

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Drug Class (USD MN)
• Selective Serotonin Reuptake Inhibitors (SSRIs) Market Sales by Geography (USD MN)
• Benzodiazepines Market Sales by Geography (USD MN)
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) Market Sales by Geography (USD MN)
• Beta Blockers Market Sales by Geography (USD MN)
• Analysis Market by Distribution Channel (USD MN)
• Hospital Pharmacies Market Sales by Geography (USD MN)
• Retail Pharmacies/Drug Stores Market Sales by Geography (USD MN)
• Online Pharmacies Market Sales by Geography (USD MN)
• Global Anti-Anxiety Drug Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Anti-Anxiety Drug Report
• Market Research Process
• Market Research Methodology
• Global Anti-Anxiety Drug Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Drug Class
• Market Attractiveness Analysis by Distribution Channel
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Drug Class (USD MN)
• Selective Serotonin Reuptake Inhibitors (SSRIs) Market Sales by Geography (USD MN)
• Benzodiazepines Market Sales by Geography (USD MN)
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) Market Sales by Geography (USD MN)
• Beta Blockers Market Sales by Geography (USD MN)
• Global Market Analysis by Distribution Channel (USD MN)
• Hospital Pharmacies Market Sales by Geography (USD MN)
• Retail Pharmacies/Drug Stores Market Sales by Geography (USD MN)
• Online Pharmacies Market Sales by Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

The global demand for Anti-Anxiety Drug Market is presumed to reach the market size of nearly USD 25.01 Billion by 2032 from USD 15.74 Billion in 2023 with a CAGR of 5.28% under the study period 2024 - 2032.

Anti-anxiety drugs, also known as anxiolytics, are medications designed to relieve symptoms of anxiety disorders. These disorders are mental health conditions characterized by excessive worry, fear, or nervousness, often leading to significant distress or impairment in daily functioning. These drugs work by affecting the central nervous system to reduce the intensity of anxiety symptoms.

MARKET DYNAMICS

The anti-anxiety drug market is propelled by several interconnected factors. Rising global awareness and acceptance of mental health issues, coupled with an increasing prevalence of anxiety disorders, contribute to a growing demand for anti-anxiety medications. Ongoing advancements in pharmaceutical research and development lead to the discovery of novel compounds and formulations, enhancing the effectiveness of these medications. The aging global population, characterized by a higher susceptibility to anxiety disorders, further boosts market growth. Additionally, modern lifestyles with elevated stress levels, expanding healthcare infrastructure, and changing regulatory environments supporting mental health research contribute to the market's expansion. Increased prescription rates and technological advancements in treatment modalities, such as telemedicine and digital health, also play pivotal roles. However, challenges include concerns about over-prescription, potential side effects, and the need for a comprehensive mental health approach encompassing therapy and lifestyle interventions.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of anti-anxiety drug. The growth and trends of anti-anxiety drug industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the anti-anxiety drug market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Benzodiazepines
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
• Beta Blockers

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies/Drug Stores
• Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Anti-Anxiety Drug market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Anti-Anxiety Drug market include Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca plc, Roche Holding AG, Forest Laboratories (a subsidiary of Allergan, now part of AbbVie), Bristol Myers Squibb Company, Sanofi S.A., Lundbeck A/S. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . ANTI-ANXIETY DRUG - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Drug Class
  • 3.7.2 Market Attractiveness Analysis By Distribution Channel
  • 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ANTI-ANXIETY DRUG MARKET ANALYSIS BY DRUG CLASS

• 5.1 Overview by Drug Class
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Drug Class
• 5.4 Selective Serotonin Reuptake Inhibitors (SSRIs) Historic and Forecast Sales by Regions
• 5.5 Benzodiazepines Historic and Forecast Sales by Regions
• 5.6 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) Historic and Forecast Sales by Regions
• 5.7 Beta Blockers Historic and Forecast Sales by Regions

6 . GLOBAL ANTI-ANXIETY DRUG MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 6.1 Overview by Distribution Channel
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Distribution Channel
• 6.4 Hospital Pharmacies Historic and Forecast Sales by Regions
• 6.5 Retail Pharmacies/Drug Stores Historic and Forecast Sales by Regions
• 6.6 Online Pharmacies Historic and Forecast Sales by Regions

7 . GLOBAL ANTI-ANXIETY DRUG MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.3.2. North America By Segment Sales Analysis
  • 7.3.3. North America By Country Sales Analysis
  • 7.3.4. United State Sales Analysis
  • 7.3.5. Canada Sales Analysis
  • 7.3.6. Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.4.2. Europe by Segment Sales Analysis
  • 7.4.3. Europe by Country Sales Analysis
  • 7.4.4. United Kingdom Sales Analysis
  • 7.4.5. France Sales Analysis
  • 7.4.6. Germany Sales Analysis
  • 7.4.7. Italy Sales Analysis
  • 7.4.8. Russia Sales Analysis
  • 7.4.9. Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.5.2. Asia Pacific by Segment Sales Analysis
  • 7.5.3. Asia Pacific by Country Sales Analysis
  • 7.5.4. China Sales Analysis
  • 7.5.5. India Sales Analysis
  • 7.5.6. Japan Sales Analysis
  • 7.5.7. South Korea Sales Analysis
  • 7.5.8. Australia Sales Analysis
  • 7.5.9. South East Asia Sales Analysis
  • 7.5.10. Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.6.2. Latin America by Segment Sales Analysis
  • 7.6.3. Latin America by Country Sales Analysis
  • 7.6.4. Brazil Sales Analysis
  • 7.6.5. Argentina Sales Analysis
  • 7.6.6. Peru Sales Analysis
  • 7.6.7. Chile Sales Analysis
  • 7.6.8. Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.7.2. Middle East & Africa by Segment Sales Analysis
  • 7.7.3. Middle East & Africa by Country Sales Analysis
  • 7.7.4. Saudi Arabia Sales Analysis
  • 7.7.5. UAE Sales Analysis
  • 7.7.6. Israel Sales Analysis
  • 7.7.7. South Africa Sales Analysis
  • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE ANTI-ANXIETY DRUG COMPANIES

• 8.1. Anti-Anxiety Drug Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9 . COMPANY PROFILES OF ANTI-ANXIETY DRUG INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Pfizer Inc.
  • 9.3.1. Company Overview
  • 9.3.2. Company Revenue
  • 9.3.3. Products
  • 9.3.4. Recent Developments
• 9.4. Eli Lilly and Company
  • 9.4.1. Company Overview
  • 9.4.2. Company Revenue
  • 9.4.3. Products
  • 9.4.4. Recent Developments
• 9.5. GlaxoSmithKline plc
  • 9.5.1. Company Overview
  • 9.5.2. Company Revenue
  • 9.5.3. Products
  • 9.5.4. Recent Developments
• 9.6. Johnson & Johnson
  • 9.6.1. Company Overview
  • 9.6.2. Company Revenue
  • 9.6.3. Products
  • 9.6.4. Recent Developments
• 9.7. AstraZeneca plc
  • 9.7.1. Company Overview
  • 9.7.2. Company Revenue
  • 9.7.3. Products
  • 9.7.4. Recent Developments
• 9.8. Roche Holding AG
  • 9.8.1. Company Overview
  • 9.8.2. Company Revenue
  • 9.8.3. Products
  • 9.8.4. Recent Developments
• 9.9. Forest Laboratories (a subsidiary of Allergan
  • 9.9.1. Company Overview
  • 9.9.2. Company Revenue
  • 9.9.3. Products
  • 9.9.4. Recent Developments
• 9.10. now part of AbbVie)
  • 9.10.1. Company Overview
  • 9.10.2. Company Revenue
  • 9.10.3. Products
  • 9.10.4. Recent Developments
• 9.11. Bristol Myers Squibb Company
  • 9.11.1. Company Overview
  • 9.11.2. Company Revenue
  • 9.11.3. Products
  • 9.11.4. Recent Developments
• 9.12. Sanofi S.A.
  • 9.12.1. Company Overview
  • 9.12.2. Company Revenue
  • 9.12.3. Products
  • 9.12.4. Recent Developments
• 9.13. Lundbeck A/S
  • 9.13.1. Company Overview
  • 9.13.2. Company Revenue
  • 9.13.3. Products
  • 9.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies